Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer.[1] Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.[2]

Ibcasertib
Clinical data
Other namesChiauranib; CS-2164
Legal status
Legal status
  • Investigational
Identifiers
  • N-(2-aminophenyl)-6-(7-methoxyquinolin-4-yl)oxynaphthalene-1-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC27H21N3O3
Molar mass435.483 g·mol−1
3D model (JSmol)
  • COC1=CC2=NC=CC(=C2C=C1)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=C5N
  • InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31)
  • Key:BRKWREZNORONDU-UHFFFAOYSA-N

References

edit
  1. ^ "Ibcasertib - Chipscreen Biosciences". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, et al. (March 2017). "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency". Cancer Science. 108 (3): 469–477. doi:10.1111/cas.13141. PMC 5378272. PMID 28004478.